AZN.L

$14364.00

Market ClosedAs of Mar 16, 6:41 PM UTC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$14364.00
Potential Downside
23%
Whystock Fair Value$11058.71
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - General

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$222.76B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.31
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Strong income play. Yield provides a meaningful total return floor.
164.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
22.84%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.65

Recent News

Motley Fool
Mar 16, 2026

Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript

Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Kyntra Bio, Inc.'s filings with the SEC, including our most recent Form 10-K and Form 10-Q. Kyntra Bio, Inc. does not undertake any obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Insider Monkey
Mar 16, 2026

Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp

AstraZeneca PLC (NASDAQ:AZN) is one of the most profitable blue chip stocks to invest in now. Guggenheim lifted the price target on AstraZeneca PLC (NASDAQ:AZN) to 16,000 GBp from 15,500 GBp on March 10, reiterating a Buy rating on the shares and telling investors that it is updating its model after the company’s fiscal 2025 […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
The Wall Street Journal
Mar 16, 2026

AstraZeneca’s Imfinzi Gets Expanded EU Label With Approval for Gastric Cancer

The EU approval of Imfinzi for early-stage gastric and gastroesophageal cancers expands the label of one of the company’s top-selling oncology medicines.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 16, 2026

Can Merck's New Drugs & Pipeline Ease Keytruda LOE Concerns?

MRK bets on new products and a growing pipeline as Keytruda nears 2028 LOE, with $70B potential commercial opportunities projected by mid-2030s.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
The Telegraph
Mar 16, 2026

£50bn construction giant abandons London stock market

Building materials giant CRH is to quit the London Stock Exchange (LSE) in a further blow to Britain’s standing as a global financial hub.

BEARISH
Negative press. News cycle fixated on risk factors or misses.